Purpose of Review Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented. Recent Findings Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Summary Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents—such as colchicine, glucocorticoids, or NSAIDs—the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial. . . . . . Keywords Calcium pyrophosphate Chondrocalcinosis Therapy Colchicine Methotrexate Anakinra Introduction with early severe osteoarthritis (OA)—occur in younger peo- ple (in familial or sporadic forms). The usual clinical presen- Even though calcium pyrophosphate deposition disease tation is that of an acute arthritis, most frequently affecting the (CPPD)  is a common disease and a frequent cause of visits knee joint and clinically similar to gout. This similarity gave to the emergency services, it has received scant attention in the rise to the name “pseudogout.” Though inflammatory symp-
Current Rheumatology Reports – Springer Journals
Published: Apr 19, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera